| Dr Michael David Lee, MD | |
|
15004 Innovation Dr, San Diego, CA 92128-3491 | |
| (858) 487-1800 | |
| Not Available |
| Full Name | Dr Michael David Lee |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 17 Years |
| Location | 15004 Innovation Dr, San Diego, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013114933 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 036.126487 (Illinois) | Secondary |
| 207Q00000X | Family Medicine | C141193 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scripps Health | 9234033853 | 1362 |
News Archive
Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) becomes resistant to a drug targeting the abnormal protein in the cancer. It's the first time scientists have analyzed the frequency and type of drug resistance in ALK positive patients taking crizotinib.
The Associated Press/New York Times: Indiana has joined the lawsuit brought by 13 states challenging the constitutionality of a mandate on Americans to carry health insurance in the new health reform law. "State Attorney General Greg Zoeller said Monday that Indiana would be added to an amended version of the lawsuit against the law that is expected to be filed soon" (3/29).
Breakthrough in heart research: The research team from Professor Katja Schenke-Layland of the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart has discovered cell surface markers that enable the identification and isolation of living functional cardiovascular progenitor cells (CPCs).
Frost & Sullivan is pleased to announce the award of its prestigious 2010 European Influenza Vaccines Technology Innovation Award to BiondVax Pharmaceuticals for their breakthrough work on a universal influenza vaccine. This vaccine, the Multimeric-001, is designed to provide multi-season and multi-strain protection against most influenza virus strains, including both seasonal and pandemic strains, and has the potential to eliminate the need for annual flu vaccination. BiondVax is entering Phase II clinical trials for the development of the Multimeric-001 universal influenza vaccine.
› Verified 8 days ago
| Entity Name | Scripps Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881636108 PECOS PAC ID: 9234033853 Enrollment ID: O20031124000822 |
News Archive
Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) becomes resistant to a drug targeting the abnormal protein in the cancer. It's the first time scientists have analyzed the frequency and type of drug resistance in ALK positive patients taking crizotinib.
The Associated Press/New York Times: Indiana has joined the lawsuit brought by 13 states challenging the constitutionality of a mandate on Americans to carry health insurance in the new health reform law. "State Attorney General Greg Zoeller said Monday that Indiana would be added to an amended version of the lawsuit against the law that is expected to be filed soon" (3/29).
Breakthrough in heart research: The research team from Professor Katja Schenke-Layland of the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart has discovered cell surface markers that enable the identification and isolation of living functional cardiovascular progenitor cells (CPCs).
Frost & Sullivan is pleased to announce the award of its prestigious 2010 European Influenza Vaccines Technology Innovation Award to BiondVax Pharmaceuticals for their breakthrough work on a universal influenza vaccine. This vaccine, the Multimeric-001, is designed to provide multi-season and multi-strain protection against most influenza virus strains, including both seasonal and pandemic strains, and has the potential to eliminate the need for annual flu vaccination. BiondVax is entering Phase II clinical trials for the development of the Multimeric-001 universal influenza vaccine.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael David Lee, MD 10790 Rancho Bernardo Rd, Mail Drop 4s-205, San Diego, CA 92127-5705 Ph: (858) 487-1800 | Dr Michael David Lee, MD 15004 Innovation Dr, San Diego, CA 92128-3491 Ph: (858) 487-1800 |
News Archive
Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) becomes resistant to a drug targeting the abnormal protein in the cancer. It's the first time scientists have analyzed the frequency and type of drug resistance in ALK positive patients taking crizotinib.
The Associated Press/New York Times: Indiana has joined the lawsuit brought by 13 states challenging the constitutionality of a mandate on Americans to carry health insurance in the new health reform law. "State Attorney General Greg Zoeller said Monday that Indiana would be added to an amended version of the lawsuit against the law that is expected to be filed soon" (3/29).
Breakthrough in heart research: The research team from Professor Katja Schenke-Layland of the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart has discovered cell surface markers that enable the identification and isolation of living functional cardiovascular progenitor cells (CPCs).
Frost & Sullivan is pleased to announce the award of its prestigious 2010 European Influenza Vaccines Technology Innovation Award to BiondVax Pharmaceuticals for their breakthrough work on a universal influenza vaccine. This vaccine, the Multimeric-001, is designed to provide multi-season and multi-strain protection against most influenza virus strains, including both seasonal and pandemic strains, and has the potential to eliminate the need for annual flu vaccination. BiondVax is entering Phase II clinical trials for the development of the Multimeric-001 universal influenza vaccine.
› Verified 8 days ago
Dr. Kyle P. Edmonds, M.D., FAAHPM Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 W Arbor Dr # 8216, San Diego, CA 92103 Phone: 858-534-6091 Fax: 619-543-3947 | |
Jessica C. Cook, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 4291 Robbins St, San Diego, CA 92122 Phone: 858-531-5692 | |
Robina Ahmad, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 6973 Linda Vista Rd, San Diego, CA 92111 Phone: 858-279-9676 | |
Dr. Anna M Mercer, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 200 W Arbor Dr, San Diego, CA 92103 Phone: 800-926-8273 | |
Bashir A. Rawi, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4647 Zion Ave, San Diego, CA 92120 Phone: 619-528-5000 | |
Martin P. Murillo, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4647 Zion Ave, San Diego, CA 92120 Phone: 619-528-5000 | |
Erwin Guzman, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4647 Zion Ave, San Diego, CA 92120 Phone: 619-528-5000 |